The aim of this study is to compare the transcriptomic profiles of microdissected tumour tissue and the surrounding tumour stromata in metastatic CRC patients harbouring KRAS mutations and with wild-type BRAF (all progressed towards metastatic disease) through a paired sample design carried out using microarray analysis. This evidence concerns the gene KRAS and neoplasm.